Circulating Tumor Cell Market Research Report- Forecast to 2027

Circulating Tumor Cell (CTC) Market Share, Growth and Trends Analysis By Application (Research, Drug Development), Technology (CTC Enrichment, CTC Detection), End-User (Hospital & Clinics, Research & Academic Institutes, Diagnostic Centers) - Forecast Till 2027

ID: MRFR/Pharma/0854-CR | August 2018 | Region: Global | 110 pages

Circulating Tumor Cell Market Overview 


The circulating tumor cell market size is expected to grow at a CAGR of 12.60% by the end of 2027. The cancer rate is increasing every year. Due to this, the range of cancer therapies is growing rapidly in many regions. More than 9.5 million men and 8.5 million women cancer cases are recorded around the world. The most common cancers are lung and breast affecting 18.5 million of the population. Most of the population in North America, Asia Pacific and Europe suffer from these diseases. Due to this the global cancer burden is tremendous. The rising rate of cancer is the demand driving factor for the circulating tumor cell market. 


Further, the circulating tumor cells circulate the body. They circulate through the blood circulatory system and lymphatic system. A circulating tumor cell is an effective tool for cancer diagnosis. Its non-invasive procedures and advantage are gaining more popularity in the market. Due to the prevalence of cancer extensive research is going on to find better treatment. The circulating tumor cell treatment proves to be beneficial for cancer patients. The massive research programs to prevent cancer will lead to the growth of the circulating tumor cell market. Also, all these factors will contribute to the high market value during the forecast period. 


Covid analysis 


The spread of the covid 19 viruses is taking a massive dig on global markets. The pharmaceutical companies and biotech sector is facing plenty of challenges. Due to the outbreak of covid 19, the development of vaccines is happening at an exponential pace. Most of the pharmaceutical companies are vaccine candidates. The research and development investments for the drug development market are immense. 


The vaccine development and supply chain is surging. Especially, hydroxychloroquine is witnessing exceptional demand during this period.


 These changes can bring a positive impact on the circulating tumor cell market. The growth of pharmaceutical and biotech companies will lead to high demand for circulating tumor cell market. The circulating tumor cell market will receive huge investments to carry out the operations. Also, the increased RD investment will lead to a new product launch. In the forecast period, the market expansion possibilities are higher for circulating tumor cells. 


Market dynamics 



  • Crucial market drivers 


The demand for minimally invasive treatment is rising rapidly. Most cancer patients prefer these non-invasive treatments. Due to this, the investments for minimally invasive treatments are increasing in the upcoming years. The invasive treatments come with plenty of side effects. Also, the pain and slow recovery are some of the limitations. However, with non-invasive procedures the trauma and side effects are limited. Further, the recovery from cancer is better. The awareness to adopt minimally invasive treatment is growing. Before choosing complex surgeries such as chemotherapy, radiotherapy and surgeries many patients prefer less invasive treatments.


 It leads to more adoption rate of non-invasive truants. These factors positively impact the circulating tumor cells prognostic technologies market. Moreover, the prevalence of cancer is another driver for the circulating tumor cell market. As per the national cancer institute, more death rates are recorded due to cancer. Almost 50000 new cancer cases are recorded every year. Colon cancer is the most prevalent cancer in many regions. Due to genetic disorders, high consumption of alcohol and lifestyle changes cancer cells attack the body. The prevalence of cancer calls for effective treatments. Due to this, the demand for the circulating tumor cell market is surging. 



  • The market growth opportunities


The vast application of circulating tumor cells will provide exceptional growth opportunities. The circulating tumor cells are mostly used for the prediagnosis of cancer. More focus on prediagnosis, pre-treatment and pre-clinical procedures will create more development opportunities.  The pretreatment application for cancer is very less. On the other hand, the main treatments such as chemotherapy and radiotherapy are more. The pretreatments for cancer lead to quick and better recovery. Directly going for complex surgeries can lead to many side effects. More awareness about preclinical treatments will create circulating tumor cell market growth opportunities.


The key players of the circulating tumor cell market are increasing production that will grow hemangioblastoma market size. It is one of the effective classes used for pre-treatment. Also, the pre-treatment such the enrichment and isolation products are having immense demand. The more production and focus of the market towards pre-treatment will bring a positive market growth rate. 



  • The market restraint 


The high cost of diagnosis is a significant restraint of the circulating tumor cell market. Circulating tumor cell treatment may be expensive for most of the population. Due to its wider benefits and better treatment the cost is high.


The materials and drugs used in the treatment are expensive. It is a restraining factor of the market that can decline the demand. Few technical difficulties in the market disturb the circulating tumor cells treatments. Both these factors can impact the overall growth of the circulating tumor cell market in the forecast period. 



  • The market challenges 


There is still a lack of awareness about circulating tumor cell products. Most cancer patients choose chemotherapy and radiotherapy. The awareness about these mainstream cancer treatments is high in many regions. However, the awareness about pretreatments such as circulating tumor cells is less.


Lack of awareness can hamper the overall expansion of the circulating tumor cell market. Also, the unwillingness of the patients to adopt circulating tumor cells is another serious challenge. Customer’s inclination to choose a medical treatment increases demand. However, the unwillingness of the patients can slow down the demand for the circulating tumor cell market. Also, it can lessen the growth opportunities for the market. 



  • Cumulative growth analysis 


The growth rate of the market is stable in the forecast period. There are plenty of factors during the demand for the circulating tumor cell market. The customer inclination towards minimally invasive treatment is driving demand. Further, the awareness about circulating tumor cells is escalating in the forecast period.


These factors constantly stir the demand. Moreover, the prediagnosis of circulating tumor cells is creating promising opportunities for the circulating tumor cell market. There is a lack of awareness about prediagnosis treatments in the market. It is a restraining factor that affects the overall market growth. Circulating the tumor cell market is expensive it leads to less demand effect on the market. 



  • Value chain analysis 


North America is leading the circulating tumor cell detection market in the forecast period. It will record the highest revenue rates than other regions. There are successful key players in the market. Innovations and investments are high for the market in the forecast period. The key players of the circulating tumor cell market are creating new strategies to develop the market. 


There are possibilities for product variation and new product launches. Further, the key payers are introducing cost-effective versions of the circulating tumor cells. All these will lead to plenty of developments in the circulating tumour cell market. 


Segment overview 


By technology 



  • Negative enrichment 

  • CTC enrichment 

  • Positive enrichment 


By detection methods 



  • CTC Detection Methods

  • Immunocytochemical Technology

  • Molecular (RNA)-based Technology


By application 



  • Cellular communication 

  • Multiple chromosome abnormalities

  • Protein expression 

  • RNA profiling 


By end-users 



  • Diagnostics centres 

  • Hospitals and clinics

  • Research and institutions


By geography 



  • North America 

  • Asia pacific 

  • Europe 


Competitive landscape 


The competition in the circulating tumor cell market is increasing rapidly. Market expansion, acquisitions and partnership are a crucial part of the competitive landscape. 


The research segment of the market will witness maximum demand. Also, the key players are creating more awareness for the market in the forecast period. Partnership with top institutes will create more awareness of the circulating tumor cell market. 


Regional analysis 


The circulating tumor cell market is fragmented into Asia Pacific, North America and Europe. North America will lead the market with the highest demand. Also, the shares for the market will increase in the forecast period. There are plenty of developments in the market. The generation of advanced tumour cells is happening in North America. It will widen the end-users.


Also, it is undertaking plenty of companies to expand the market. Furthermore, the Asia Pacific region will witness high market expansion. There are high possibilities of cancer in this region. Every year the new type of cancer diseases are rising. Technological advancement is the key factor driving the demand in this region. Infrastructural developments will bring plenty of developments to the market. Also, many unmet diagnostics needs will provide exceptional growth opportunities in this region. The need for early detection and prevention will drive demand in North America. 


The key players of the circulating tumor cell market are 



  • STEMCELL Technologies, Inc. 

  • QIAGEN

  • Sysmex Corporation

  • Bio-Techne Corporation

  • Menarini Silicon Biosystems

  • AVIVA Biosciences

  • ScreenCell

  • Fluxion Biosciences, Inc.

  • Creativ MicroTech,

  • Biolidics Limited

  • IVDiagnostics

  • Inc Ikonisys Inc.

  • Canopus Bioscience Ltd.


Recent developments 



  1. The bicep is improving the diagnosis of cancer treatment. It received the patent to carry out molecular analysis on cancer patients. 



  1. The key players are focusing more on colorectal cancer and its treatment. 


Report overview 



  1. Market overview highlights 

  2. Analysis based upon COVID 19

  3. Explanation upon the Market Dynamics

  4. Value chain analysis

  5. Market segmentation overview

  6. The regional analysis

  7. Competitive landscape analysis

  8. Recent Developments



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   12.60% (2020-2027)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Application, Technology, End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Ikonisys Inc., Greiner Bio-One International GmbH, Thermo Fisher Scientific, SRI International, STEMCELL Technologies, Miltenyi Biotec, Menarini Silicon Biosystems, QIAGEN Hannover (QIAGEN), F. Hoffmann-La Roche Ltd, NanoString Technologies, Inc, Fluxion Biosciences, Inc., GE Healthcare, ApoCell, Advanced Cell Diagnostics, Inc. (Bio-Techne Corporation), Epic Lifesciences, Celltraffix Inc.
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers   Clinical, research and drug development


Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :


Circulating Tumor Cell Market is expected to touch a valuation of USD 28,300 million by 2023.

Circulating Tumor Cell Market stood at USD 9,393.1 million in 2017.

Circulating Tumor Cell Market can expand at a CAGR of 20.32% from 2018 to 2023.

Hospitals & clinics are predicted to be the biggest end-use segment of the Global Circulating Tumor Cell Market.

Americas can dominate the Global Circulating Tumor Cell Market.

ApoCell, F. Hoffmann-La Roche Ltd, Celltraffix Inc., QIAGEN Hannover (QIAGEN), STEMCELL Technologies, Thermo Fisher Scientific, Greiner Bio-One International GmbH, SRI International, GE Healthcare, Ikonisys Inc., NanoString Technologies, Inc, Fluxion Biosciences, Inc., Miltenyi Biotec, Menarini Silicon Biosystems, Advanced Cell Diagnostics, Inc. (Bio-Techne Corporation), and Epic Lifesciences are the major players of the Global Circulating Tumor Cell Market.

1 Report Prologue

2 Market Introduction

2.1 Assumptions & Limitations 16

3 Research Methodology

3.1 Research Process 19

3.2 Primary Research 19

3.3 Secondary Research 19

3.4 Market Size Estimation 20

4 Market Dynamics

4.1 Introduction 22

4.2 Drivers 22

4.2.1 Rising Occurrence Of Cancer 22

4.2.2 Increasing Research And Development 22

4.2.3 Rising Geriatric Population 23

4.3 Restraint 23

4.3.1 High Cost Of CTC Tests And Instruments 23

4.4 Opportunity 23

4.4.1 Entering Developing Economies 23

5 Market Factor Analysis

5.1 Value Chain Analysis 25

5.1.1 R&D And Designing 25

5.1.2 Manufacturing 25

5.1.3 Distribution & Sales 26

5.1.4 Post-Sales Review 26

5.2 Porter’s Five Forces Model 26

5.2.1 Bargaining Power Of Suppliers 27

5.2.2 Bargaining Power Of Buyers 27

5.2.3 Threat Of New Entrants 27

5.2.4 Threat Of Substitutes 27

5.2.5 Intensity Of Rivalry 27

6 Circulating Tumor Cell Market, By Application

6.1 Introduction 29

6.2 Clinical 30

6.3 Research 30

6.4 Drug Development 31

7 Circulating Tumor Cell Market, By Technology

7.1 Introduction 33

7.2 CTC Enrichment 34

7.3 CTC Detection 34

7.4 Combined Enrichment And Separation Of CTC (CTC Analysis) 34

8 Circulating Tumor Cell Market, By End-User

8.1 Introduction 36

8.2 Hospital & Clinics 37

8.3 Research & Academic Institutes 37

8.4 Diagnostic Centers 37

9 Global Circulating Tumor Cell Market, By Region

9.1 Introduction 39

9.2 Americas 40

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.2.1 North America 42

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.2.1.1 U.S 44

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.2.1.2 Canada 46

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.2.2 South America 47

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.3 Europe 50

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.3.1 Western Europe 52

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.3.1.1 Germany 54

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.3.1.2 U.K 56

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.3.1.3 France 57

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.3.1.4 Spain 59

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.3.1.5 Italy 61

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.3.1.6 Rest Of Western Europe 62

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.3.2 Eastern Europe 64

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.4 Asia Pacific 66

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.4.1 China 68

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.4.2 Japan 70

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.4.3 India 71

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.4.4 Australia 73

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.4.5 Republic Of Korea 75

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.4.6 Rest Of Asia Pacific 76

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.5 Middle East & Africa 79

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.5.1 Middle East 81

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

9.5.2 Africa 83

Circulating Tumor Cell Market, By Application

Circulating Tumor Cell Market, By Technology

Circulating Tumor Cell Market, By End-User

10 Competitive Landscape

10.1 Introduction 86

11 Company Profiles

11.1 Greiner Bio-One International GmbH 88

11.1.1 Company Overview 88

11.1.2 Financial Overview 88

11.1.3 Products Offering 89

11.1.4 Key Developments 89

11.1.5 SWOT Analysis 89

11.1.6 Key Strategy 89

11.2 Ikonisys Inc. 90

11.2.1 Company Overview 90

11.2.2 Financial Overview 90

11.2.3 Products Offering 90

11.2.4 Key Developments 90

11.2.5 SWOT Analysis 90

11.2.6 Key Strategy 90

11.3 Thermo Fisher Scientific 91

11.3.1 Company Overview 91

11.3.2 Financial Overview 91

11.3.3 Products Offering 92

11.3.4 Key Developments 92

11.3.5 SWOT Analysis 92

11.3.6 Key Strategy 92

11.4 SRI International 93

11.4.1 Company Overview 93

11.4.2 Financial Overview 93

11.4.3 Products Offering 93

11.4.4 Key Developments 93

11.4.5 SWOT Analysis 94

11.4.6 Key Strategy 94

11.5 STEMCELL Technologies 95

11.5.1 Company Overview 95

11.5.2 Financial Overview 95

11.5.3 Products Offering 95

11.5.4 Key Developments 95

11.5.5 SWOT Analysis 95

11.5.6 Key Strategy 95

11.6 Miltenyi Biotec 96

11.6.1 Company Overview 96

11.6.2 Financial Overview 96

11.6.3 Products Offering 96

11.6.4 Key Developments 96

11.6.5 SWOT Analysis 96

11.6.6 Key Strategy 97

11.7 Menarini Silicon Biosystems 98

11.7.1 Company Overview 98

11.7.2 Financial Overview 98

11.7.3 Products Offering 98

11.7.4 Key Developments 98

11.7.5 SWOT Analysis 98

11.7.6 Key Strategy 98

11.8 QIAGEN Hannover (QIAGEN) 99

11.8.1 Company Overview 99

11.8.2 Financial Overview 99

11.8.3 Products Offering 99

11.8.4 Key Developments 100

11.8.5 SWOT Analysis 100

11.8.6 Key Strategy 100

11.9 F. Hoffmann-La Roche Ltd 101

11.9.1 Company Overview 101

11.9.2 Financial Overview 101

11.9.3 Products Offering 102

11.9.4 Key Developments 102

11.9.5 SWOT Analysis 102

11.9.6 Key Strategy 102

11.10 NanoString Technologies, Inc. 103

11.10.1 Company Overview 103

11.10.2 Financial Overview 103

11.10.3 Products Offering 103

11.10.4 Key Developments 104

11.10.5 SWOT Analysis 104

11.10.6 Key Strategy 104

11.11 Fluxion Biosciences, Inc. 105

11.11.1 Company Overview 105

11.11.2 Financial Overview 105

11.11.3 Products Offering 105

11.11.4 Key Developments 105

11.11.5 SWOT Analysis 105

11.11.6 Key Strategy 106

11.12 GE Healthcare 107

11.12.1 Company Overview 107

11.12.2 Financial Overview 107

11.12.3 Products Offering 107

11.12.4 Key Developments 108

11.12.5 SWOT Analysis 108

11.12.6 Key Strategy 108

12 Appendix

12.1 Discussion Blue Print 110

13 List Of Tables

TABLE 1 GLOBAL CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2020-2027 (USD MILLION) 29

TABLE 2 GLOBAL CIRCULATING TUMOR CELL MARKET FOR CLINICAL APPLICATION 2020-2027 (USD MILLION) 30

TABLE 3 GLOBAL CIRCULATING TUMOR CELL MARKET FOR RESEARCH APPLICATION 2020-2027 (USD MILLION) 30

TABLE 4 GLOBAL CIRCULATING TUMOR CELL MARKET FOR DRUG DEVELOPMENT APPLICATION 2020-2027 (USD MILLION) 31

TABLE 5 GLOBAL CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 33

TABLE 6 GLOBAL CIRCULATING TUMOR CELL MARKET FOR CTC ENRICHMENT 2020-2027 (USD MILLION) 34

TABLE 7 GLOBAL CIRCULATING TUMOR CELL MARKET FOR CTC DETECTION 2020-2027 (USD MILLION) 34

TABLE 8 GLOBAL CIRCULATING TUMOR CELL MARKET FOR COMBINED ENRICHMENT AND SEPARATION OF CTC (CTC ANALYSIS) 2020-2027

(USD MILLION) 34

TABLE 9 GLOBAL CIRCULATING TUMOR CELL MARKET, BY END-USER 2020-2027 (USD MILLION) 36

TABLE 10 GLOBAL CIRCULATING TUMOR CELL MARKET FOR HOSPITAL & CLINICS 2020-2027 (USD MILLION) 37

TABLE 11 GLOBAL CIRCULATING TUMOR CELL MARKET FOR RESEARCH & ACADEMIC INSTITUTES 2020-2027 (USD MILLION) 37

TABLE 12 GLOBAL CIRCULATING TUMOR CELL MARKET FOR DIAGNOSTIC CENTERS 2020-2027 (USD MILLION) 37

TABLE 13 GLOBAL CIRCULATING TUMOR CELL MARKET, BY REGION 2020-2027 (USD MILLION) 39

TABLE 14 AMERICAS CIRCULATING TUMOR CELL MARKET, BY REGION 2020-2027 (USD MILLION) 40

TABLE 15 AMERICAS CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2020-2027 (USD MILLION) 41

TABLE 16 AMERICAS CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2020-2027 (USD MILLION) 41

TABLE 17 AMERICAS CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2020-2027 (USD MILLION) 41

TABLE 18 AMERICAS CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 42

TABLE 19 AMERICAS CIRCULATING TUMOR CELL MARKET, BY END USER 2020-2027 (USD MILLION) 42

TABLE 20 NORTH AMERICA CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2020-2027 (USD MILLION) 42

TABLE 21 NORTH AMERICA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2020-2027 (USD MILLION) 43

TABLE 22 NORTH AMERICA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2020-2027 (USD MILLION) 43

TABLE 23 NORTH AMERICA CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 43

TABLE 24 NORTH AMERICA CIRCULATING TUMOR CELL MARKET, BY END USER 2020-2027 (USD MILLION) 44

TABLE 25 U.S CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2020-2027 (USD MILLION) 44

TABLE 26 U.S CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2020-2027 (USD MILLION) 44

TABLE 27 U.S CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2020-2027 (USD MILLION) 45

TABLE 28 U.S CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 45

TABLE 29 U.S CIRCULATING TUMOR CELL MARKET, BY END USER 2020-2027 (USD MILLION) 45

TABLE 30 CANADA CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2020-2027 (USD MILLION) 46

TABLE 31 CANADA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2020-2027 (USD MILLION) 46

TABLE 32 CANADA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2020-2027 (USD MILLION) 46

TABLE 33 CANADA CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 47

TABLE 34 CANADA CIRCULATING TUMOR CELL MARKET, BY END USER 2020-2027 (USD MILLION) 47

TABLE 35 SOUTH AMERICA CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2020-2027 (USD MILLION) 47

TABLE 36 SOUTH AMERICA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2020-2027 (USD MILLION) 48

TABLE 37 SOUTH AMERICA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2020-2027 (USD MILLION) 48

TABLE 38 SOUTH AMERICA CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 48

TABLE 39 SOUTH AMERICA CIRCULATING TUMOR CELL MARKET, BY END USER 2020-2027 (USD MILLION) 49

TABLE 40 EUROPE CIRCULATING TUMOR CELL MARKET, BY REGION 2020-2027 (USD MILLION) 50

TABLE 41 EUROPE CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2020-2027 (USD MILLION) 51

TABLE 42 EUROPE CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2020-2027 (USD MILLION) 51

TABLE 43 EUROPE CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2020-2027 (USD MILLION) 51

TABLE 44 EUROPE CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 52

TABLE 45 EUROPE CIRCULATING TUMOR CELL MARKET, BY END USER 2020-2027 (USD MILLION) 52

TABLE 46 WESTERN EUROPE CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2020-2027 (USD MILLION) 52

TABLE 47 WESTERN EUROPE CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2020-2027 (USD MILLION) 53

TABLE 48 WESTERN EUROPE CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2020-2027 (USD MILLION) 53

TABLE 49 WESTERN EUROPE CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 53

TABLE 50 WESTERN EUROPE CIRCULATING TUMOR CELL MARKET, BY END USER 2020-2027 (USD MILLION) 54

TABLE 51 GERMANY CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2020-2027 (USD MILLION) 54

TABLE 52 GERMANY CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2020-2027 (USD MILLION) 54

TABLE 53 GERMANY CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2020-2027 (USD MILLION) 55

TABLE 54 GERMANY CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 55

TABLE 55 GERMANY CIRCULATING TUMOR CELL MARKET, BY END USER 2020-2027 (USD MILLION) 55

TABLE 56 U.K CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2020-2027 (USD MILLION) 56

TABLE 57 U.K CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2020-2027 (USD MILLION) 56

TABLE 58 U.K CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2020-2027 (USD MILLION) 56

TABLE 59 U.K CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 57

TABLE 60 U.K CIRCULATING TUMOR CELL MARKET, BY END USER 2020-2027 (USD MILLION) 57

TABLE 61 FRANCE CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2020-2027 (USD MILLION) 57

TABLE 62 FRANCE CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2020-2027 (USD MILLION) 58

TABLE 63 FRANCE CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2020-2027 (USD MILLION) 58

TABLE 64 FRANCE CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 58

TABLE 65 FRANCE CIRCULATING TUMOR CELL MARKET, BY END USER 2020-2027 (USD MILLION) 59

TABLE 66 SPAIN CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2020-2027 (USD MILLION) 59

TABLE 67 SPAIN CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2020-2027 (USD MILLION) 59

TABLE 68 SPAIN CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2020-2027 (USD MILLION) 60

TABLE 69 SPAIN CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 60

TABLE 70 SPAIN CIRCULATING TUMOR CELL MARKET, BY END USER 2020-2027 (USD MILLION) 60

TABLE 71 ITALY CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2020-2027 (USD MILLION) 61

TABLE 72 ITALY CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2020-2027 (USD MILLION) 61

TABLE 73 ITALY CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2020-2027 (USD MILLION) 61

TABLE 74 ITALY CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 62

TABLE 75 ITALY CIRCULATING TUMOR CELL MARKET, BY END USER 2020-2027 (USD MILLION) 62

TABLE 76 REST OF WESTERN EUROPE CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2020-2027 (USD MILLION) 62

TABLE 77 REST OF WESTERN EUROPE CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2020-2027 (USD MILLION) 63

TABLE 78 REST OF WESTERN EUROPE CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2020-2027 (USD MILLION) 63

TABLE 79 REST OF WESTERN EUROPE CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 63

TABLE 80 REST OF WESTERN EUROPE CIRCULATING TUMOR CELL MARKET, BY END USER 2020-2027 (USD MILLION) 64

TABLE 81 EASTERN EUROPE CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2020-2027 (USD MILLION) 64

TABLE 82 EASTERN EUROPE CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2020-2027 (USD MILLION) 64

TABLE 83 EASTERN EUROPE CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2020-2027 (USD MILLION) 65

TABLE 84 EASTERN EUROPE CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 65

TABLE 85 EASTERN EUROPE CIRCULATING TUMOR CELL MARKET, BY END USER 2020-2027 (USD MILLION) 65

TABLE 86 ASIA PACIFIC CIRCULATING TUMOR CELL MARKET, BY COUNTRY 2020-2027 (USD MILLION) 66

TABLE 87 ASIA PACIFIC CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2020-2027 (USD MILLION) 66

TABLE 88 ASIA PACIFIC CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2020-2027 (USD MILLION) 67

TABLE 89 ASIA PACIFIC CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2020-2027 (USD MILLION) 67

TABLE 90 ASIA PACIFIC CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 67

TABLE 91 ASIA PACIFIC CIRCULATING TUMOR CELL MARKET, BY END USER 2020-2027 (USD MILLION) 68

TABLE 92 CHINA CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2020-2027 (USD MILLION) 68

TABLE 93 CHINA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2020-2027 (USD MILLION) 68

TABLE 94 CHINA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2020-2027 (USD MILLION) 69

TABLE 95 CHINA CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 69

TABLE 96 CHINA CIRCULATING TUMOR CELL MARKET, BY END USER 2020-2027 (USD MILLION) 69

TABLE 97 JAPAN CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2020-2027 (USD MILLION) 70

TABLE 98 JAPAN CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2020-2027 (USD MILLION) 70

TABLE 99 JAPAN CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2020-2027 (USD MILLION) 70

TABLE 100 JAPAN CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 71

TABLE 101 JAPAN CIRCULATING TUMOR CELL MARKET, BY END USER 2020-2027 (USD MILLION) 71

TABLE 102 INDIA CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2020-2027 (USD MILLION) 71

TABLE 103 INDIA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2020-2027 (USD MILLION) 72

TABLE 104 INDIA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2020-2027 (USD MILLION) 72

TABLE 105 INDIA CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 72

TABLE 106 INDIA CIRCULATING TUMOR CELL MARKET, BY END USER 2020-2027 (USD MILLION) 73

TABLE 107 AUSTRALIA CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2020-2027 (USD MILLION) 73

TABLE 108 AUSTRALIA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2020-2027 (USD MILLION) 73

TABLE 109 AUSTRALIA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2020-2027 (USD MILLION) 74

TABLE 110 AUSTRALIA CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 74

TABLE 111 AUSTRALIA CIRCULATING TUMOR CELL MARKET, BY END USER 2020-2027 (USD MILLION) 74

TABLE 112 REPUBLIC OF KOREA CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2020-2027 (USD MILLION) 75

TABLE 113 REPUBLIC OF KOREA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2020-2027 (USD MILLION) 75

TABLE 114 REPUBLIC OF KOREA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2020-2027 (USD MILLION) 75

TABLE 115 REPUBLIC OF KOREA CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 76

TABLE 116 REPUBLIC OF KOREA CIRCULATING TUMOR CELL MARKET, BY END USER 2020-2027 (USD MILLION) 76

TABLE 117 REST OF ASIA PACIFIC CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2020-2027 (USD MILLION) 76

TABLE 118 REST OF ASIA PACIFIC CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2020-2027 (USD MILLION) 77

TABLE 119 REST OF ASIA PACIFIC CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2020-2027 (USD MILLION) 77

TABLE 120 REST OF ASIA PACIFIC CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 77

TABLE 121 REST OF ASIA PACIFIC CIRCULATING TUMOR CELL MARKET, BY END USER 2020-2027 (USD MILLION) 78

TABLE 122 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET, BY REGION 2020-2027 (USD MILLION) 79

TABLE 123 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2020-2027 (USD MILLION) 79

TABLE 124 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2020-2027 (USD MILLION) 80

TABLE 125 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF

MALIGNANCIES TYPE 2020-2027 (USD MILLION) 80

TABLE 126 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 80

TABLE 127 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET, BY END USER 2020-2027 (USD MILLION) 81

TABLE 128 MIDDLE EAST CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2020-2027 (USD MILLION) 81

TABLE 129 MIDDLE EAST CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2020-2027 (USD MILLION) 81

TABLE 130 MIDDLE EAST CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2020-2027 (USD MILLION) 82

TABLE 131 MIDDLE EAST CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 82

TABLE 132 MIDDLE EAST CIRCULATING TUMOR CELL MARKET, BY END USER 2020-2027 (USD MILLION) 82

TABLE 133 AFRICA CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2020-2027 (USD MILLION) 83

TABLE 134 AFRICA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY TYPE 2020-2027 (USD MILLION) 83

TABLE 135 AFRICA CIRCULATING TUMOR CELL MARKET, FOR CLINICAL APPLICATION BY DIAGNOSIS & MANAGEMENT OF TUMOR

MALIGNANCIES TYPE 2020-2027 (USD MILLION) 83

TABLE 136 AFRICA CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2020-2027 (USD MILLION) 84

TABLE 137 AFRICA CIRCULATING TUMOR CELL MARKET, BY END USER 2020-2027 (USD MILLION) 84

TABLE 138 TOP MANUFACTURERS IN THE GLOBAL CIRCULATING TUMOR CELLS MARKET 2020 86

14 List Of Figures

FIGURE 1 MARKET STRUCTURE 17

FIGURE 2 RESEARCH PROCESS 19

FIGURE 3 DRO ANALYSIS OF GLOBAL CIRCULATING TUMOR CELL MARKET 22

FIGURE 4 VALUE CHAIN: GLOBAL CIRCULATING TUMOR CELL MARKET 25

FIGURE 5 PORTER’S FIVE FORCES MODEL: GLOBAL CIRCULATING TUMOR CELL MARKET 26

FIGURE 6 GLOBAL CIRCULATING TUMOR CELL MARKET, BY APPLICATION 2020 & 2027 (USD MILLION) 30

FIGURE 7 GLOBAL CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY 2020 & 2027 (USD MILLION) 33

FIGURE 8 GLOBAL CIRCULATING TUMOR CELL MARKET, BY END-USER 2020 & 2027 (USD MILLION) 36

FIGURE 9 GLOBAL CIRCULATING TUMOR CELL MARKET SHARE, BY REGION 2020 (%) 40

FIGURE 10 AMERICAS CIRCULATING TUMOR CELL MARKET SHARE, BY REGION 2020 (%) 40

FIGURE 11 EUROPE CIRCULATING TUMOR CELL MARKET SHARE, BY REGION 2020 (%) 50

FIGURE 12 ASIA PACIFIC CIRCULATING TUMOR CELL MARKET SHARE, BY REGION 2020 (%) 66

FIGURE 13 MIDDLE EAST & AFRICA CIRCULATING TUMOR CELL MARKET SHARE, BY REGION 2020 (%) 79

Circulating Tumor Cells Market: Competitive Landscape


The circulating tumor cells market is characterized by the presence of many global, regional, and local vendors. The market is highly competitive with all the players competing to gain market share. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront the market growth. The vendors compete based on cost, quality, and reliability. It is decisive for the vendors to provide cost-efficient and high-quality products, to survive and succeed in an intensely competitive market environment.


The growth of the circulating tumor cell market players is dependent on market conditions, government support, and industry development. Thus, major players should focus on expanding geographically and improving their products. They primarily focus on the development of novel products. Although international players are dominating the market, regional players with small market shares also have a presence. International players are likely to strengthen their presence worldwide through acquisitions during the forecast period. It has also been estimated that improvement of the global economic scenario combined with efforts to enhance the infrastructure in emerging nations, is fueling the circulating tumor cell market growth, thereby making it an ideal time for new products and increase the global circulating tumor cell market share.


Players with better technical and financial resources can develop innovative products. Therefore, vendors must develop new technologies and stay abreast of emerging technologies that could affect the continuing competitiveness of their treatment lines in the market.



  1. Hoffmann-La Roche Ltd has a vast product portfolio in the circulating tumor cells industry. The company also has a wide geographic presence as it operates in various countries across the world. It has a significant presence in North America, Europe, and the Middle East and Africa, with commercial, manufacturing, and research facilities in more than one dozen countries.